Author:
Ke Qiao,He Jian,Cai Linsheng,Lei Xiaojuan,Huang Xinhui,Li Ling,Liu Jingfeng,Guo Wuhua
Abstract
AbstractThis study aimed to assess the safety and efficacy of interventional embolization in cirrhotic patients with refractory hepatic encephalopathy (HE) associated with large spontaneous portosystemic shunts (SPSS). Inverse probability of treatment weighting (IPTW) was employed to minimize potential bias. A total of 123 patients were included in this study (34 in the embolization group and 89 in the control group). In the unadjusted cohort, the embolization group demonstrated significantly better liver function, a larger total area of SPSS, and a higher percentage of patients with serum ammonia levels > 60 µmol/L and the presence of hepatocellular carcinoma (HCC) (all P < 0.05). In the IPTW cohort, baseline characteristics were comparable between the two groups (all P > 0.05). Patients in the embolization group exhibited significantly longer HE-free survival compared to the control group in both the unadjusted and IPTW cohorts (both P < 0.05). Subsequent subgroup analyses indicated that patients with serum ammonia level > 60 μmol/L, hepatopetal flow within the portal trunk, the presence of solitary SPSS, a baseline HE grade of II, and the absence of HCC at baseline showed statistically significant benefit from embolization treatment (all P < 0.05). No early procedural complications were observed in the embolization group. The incidence of long-term postoperative complications was comparable to that in the control group (all P > 0.05). Hence, interventional embolization appears to be a safe and effective treatment modality for cirrhotic patients with refractory HE associated with large SPSS. However, the benefits of embolization were discernible only in a specific subset of patients.
Funder
the Joint Funds for the Innovation of Science and Technology of Fujian province, Fujian, P.R.C
the Scientific Foundation of Fuzhou Municipal Health Commission, Fujian, P.R.C
the Key Clinical Specialty Discipline Construction Program of Fuzhou, Fujian, P.R.C
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J. Hepatol. 77, 807–824 (2022).
2. Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis. Zhonghua nei ke za zhi 57(10), 705–718 (2018).
3. Ridola, L. et al. Clinical management of type C hepatic encephalopathy. United Eur. Gastroenterol. J. 8, 536–543 (2020).
4. Elsaid, M. I. & Rustgi, V. K. Epidemiology of hepatic encephalopathy. Clin. Liver Dis. 24, 157–174 (2020).
5. Shaheen, A. A., Nguyen, H. H., Congly, S. E., Kaplan, G. G. & Swain, M. G. Nationwide estimates and risk factors of hospital readmission in patients with cirrhosis in the United States. Liver Int. 39, 878–884 (2019).